PPT-Guidance BY Dr Chitrangad

Upadhyay bdkbZ amp 3         funsZ ku dk vFkZ funsZ ku ds fl kUrksa dk LiVhdjk ijke kZ dh vo kkjkk amp funsZf kr. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the not ice announcing the availa bility of the draft guidance Submit electronic comments to httpwwwregulationsgov S Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit written comments to the Di vision of Dockets Mana 5741157455574535745357445574545746057459573765744157454574445737657459574615744757447574455745957460574495745557454574595737657458574455744757441574585744457449574545744757376574605744857449574595737657444574585744157446574605737657444 Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic com ments to httpwwwregulationsgov Su Comments and suggestions regarding this draft document should be subm itted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Management H Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments on the draft guidance to http Comments and suggestions regarding this draft document should be submitted within 60 calendar days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Mana Federal Register Federal Register US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research CDER January 2010 Clinical Medical brPage 2br Guidance for Industry Assessment of Abuse Potential of Dr Comments and suggestions regarding this draft docu ment should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Management H Michel Le Straad Authors job title s Clinical Commissioner and Designated Nurse for Vulnerable Adults for the Trafford Health Economy Directorates Mental Health Commissioning Document status Final Supersedes None Approval NHS Adult Safeguarding Netw com A Framework for Architectural Guidance Development. Mohsen . Anvaari. Norwegian University of Science and . Technology. Trondheim, . Norway. mohsena@idi.ntnu.no. . Olaf . Zimmermann. University of Applied Sciences of Eastern Switzerland . Richard Swannell. WRAP. Introduction. Why develop guidance?. What does it contain?. Conclusions and next steps.. Why?. To support the Save Food initiative. To help Governments, Municipalities and businesses to drive change. Meaning, Nature and Scope of Guidance. Meaning of Guidance: . Literally guidance means . 'to direct‘, 'to point out‘, 'to show the path‘.. . It is the assistance or help rendered by a more experienced person to a less experienced person to solve certain major problems of the individual i.e. educational, vocational, personal etc. .